Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2

Conditions

Stomach Neoplasms 132Pancreatic Neoplasms 36Esophageal Neoplasms 19Biliary Tract Neoplasms 18Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 10Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Gastrointestinal Neoplasms 6Nasopharyngeal Carcinoma 5Colonic Neoplasms 5Adenocarcinoma 5Neoplasms 4Head and Neck Neoplasms 4Advanced Pancreatic Cancer 4Advanced Gastric Cancer 4Recurrence 3Rectal Neoplasms 3Gastric Adenocarcinoma 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2NSCLC 2Locally Advanced Pancreatic Cancer 2Gastric Cancer Peritoneal Metastases 2Gallbladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms × S 1 (combination) × Clear all
NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Ruijin Hospital

Phase 3 Recruiting
387 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT07018063 2025-06-12

YOUNG-NEOS

Peking University People's Hospital

Phase 2 Not yet recruiting
35 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT00400023 2024-09-03

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00479076 2011-01-26

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Sanofi

Phase 1 Completed
22 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡